EGFR and neoplasm: Even though they have demonstrated high uptake in EGFR-positive tumors, their large molecular size (∼150 kDa) and consequential slow hepatobiliary clearance (e.g., cetuximab half-life in humans is about 95 h) resulted in poor contrast between tumor and normal tissues on images acquired at earlier time points (11,12).